Clinical Trials Logo

Clinical Trial Summary

Population pharmacokinetic modeling mathematically describes the pharmacokinetics of a drug and the variables likely to influence it in a "typical" patient population. We propose to model a Bayesian estimator, taking into account the individual factors that influence exposure to the piperacillin / tazobactam combination in a target population of sepsis, to allow for early assessment of serum Piperacillin / Tazobactam concentration profiles. optimization of dosing regimens. Indeed, pharmacokinetic tools of this type are already regularly successfully applied for other classes of antibiotics or immunosuppressants whose therapeutic index is narrow. They reduce the toxic risk and optimize the effectiveness of these treatments.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03748095
Study type Observational
Source University Hospital, Rouen
Contact
Status Recruiting
Phase
Start date March 12, 2019
Completion date June 15, 2024